Many health experts believe that the Covid-19 vaccine candidate NVX-CoV237 from Novavax offers potential advantages over competitors including Pfizer-BioNTech, Moderna, Johnson & Johnson, and AstraZeneca-Oxford.
Novavax announced a Memorandum of Understanding (MOU) with Gavi, the Vaccine Alliance, to provide 1.1 billion doses of the company’s Covid-19 vaccine candidate NVX-CoV2373 for the COVAX Facility.
The United States under President Joe Biden intends to join the COVAX vaccine facility that aims to deliver coronavirus vaccines to poor countries, his chief medical adviser, Anthony Fauci, told the World Health Organization (WHO).
The U.S. Food and Drug Administration gave Emergency Use Authorization (EUA) to a Covid-19 test developed by Roche that measures antibodies within the blood.
Amgen, UCB and Takeda launched a global trial to identify whether any of three different drugs can reduce the severity of Covid-19 in hospitalized patients by moderating the immune system’s response to the disease.
French drugmaker Sanofi and Britain’s GlaxoSmithKline will supply 200 million doses of their Covid-19 candidate vaccine to a global inoculation scheme backed by the World Health Organization.
The Takeda Pharmaceutical Co.-led group that is developing a blood plasma treatment for Covid-19 started manufacturing while the late-stage trial to determine whether the hyperimmune globulin therapy works is ongoing, Chief Executive Christophe Weber said.
Japan’s Takeda Pharmaceutical said on Friday an alliance of drugmakers the company spearheads enrolled the first patient in a global clinical trial of a blood plasma treatment for Covid-19 after months of regulatory delays.
The National Institute of Health (NIH) reinstated a $7.5 million grant to the nonprofit research organization EcoHealth Alliance.
AbbVie and Harvard University entered into a $30 million collaborative research alliance to develop therapies against emergent viral infections, with a focus on those caused by coronaviruses and by viruses that lead to hemorrhagic fever.